Posteo
Photoforlife
Photoforlife
The On-Chain Perps Wars — 5 Platforms Fighting Hyperliquid’s Throne $HYPE captured 70% of on-chain perps. The other 30% is being fought over by hungry challengers. Most will fail. A few could surprise. Setup. On-chain perps grew from $5B daily to $30B+ in 18 months. Real fees. Real disruption to CEXs. Market big enough for 2-3 winners. Challengers on OKX. $DRIFT — Solana’s biggest perps platform. Benefits from any SOL rotation. Could become “Solana’s Hyperliquid” when SOL ETF approves. $DYDX — OG perps DEX rebuilt on Cosmos. Lost momentum to HYPE but tech still works. Asymmetric setup at depressed levels. $GMX — Pioneer on Arbitrum. Real cash flow despite losing share. Multi-chain expansion underway. $INJ — DeFi derivatives on Cosmos. Deflationary tokenomics working. Asian institutional interest building. $JUP — Solana DEX aggregator expanding into perps. Massive distribution through SOL ecosystem. Why matters. CLARITY Act legitimizes on-chain perps. ETH and SOL ETFs bring institutional money. Stablecoin yields make capital efficiency critical. Adjacent winners. $JTO captures MEV from Solana perps. $LDO benefits from staking collateral demand. $EIGEN restaking creates perps capital efficiency. $LINK provides oracles every platform needs. Stocks. $CBRS uses on-chain infrastructure. $NVDA validators run on chips. $SPACEX could adopt perps for hedging. Risks. Regulatory crackdowns intensifying. Token unlocks pressuring prices. HYPE dominance compounding. New entrants like $EDGE testing market. Framework. Long 1-2 platforms ($DRIFT for SOL, $INJ for Cosmos). Don’t bet against $HYPE. Watch HYPE pullbacks as entries. Hidden truth. Most “Hyperliquid killers” die. The 1-2 capturing ecosystem niches could 5-10x. But $HYPE keeps eating broader pie. Position with leader. Diversify into challengers. Survive consolidation. Not financial advice — DYOR. #Perps #HYPEShortSqueeze

Deslinde de responsabilidades: el contenido de OKX Orbit se brinda únicamente con fines informativos. Más información

Respuestas

Aún no hay comentarios. ¡Envía la primera respuesta!